Recent Analysts’ Ratings Changes for Qiagen (QGEN)

Qiagen (NYSE: QGEN) has recently received a number of price target changes and ratings updates:

• 10/28/2026 – Qiagen was downgraded by Barclays from “overweight” to “equal weight”. They now have a $53.00 price target on the stock, down from $55.00.
• 10/26/2026 – Qiagen had its “neutral” rating reaffirmed by Citigroup. They now have a $52.00 price target on the stock, up from $45.00.
• 10/26/2026 – Qiagen had its price target raised by Citigroup from $45.00 to $52.00. They now have a “hold” rating on the stock.
• 10/22/2026 – Qiagen was downgraded by DZ Bank from “strong-buy” to “hold”.
• 10/22/2026 – Qiagen was downgraded by JPMorgan Chase & Co. from “overweight” to “neutral”. They now have a $52.00 price target on the stock, down from $55.00.
• 10/22/2026 – Qiagen had its price target raised by Robert W. Baird from $50.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/14/2026 – Qiagen had its price target raised by JPMorgan Chase & Co. from $50.00 to $55.00. They now have an “overweight” rating on the stock.
• 9/11/2026 – Qiagen was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/11/2026 – Qiagen had its “overweight” rating reaffirmed by Morgan Stanley.

Qiagen Stock Performance

QGEN opened at $50.37 on Monday. The firm has a market capitalization of $10.38 billion, a P/E ratio of 27.52, a price-to-earnings-growth ratio of 5.00 and a beta of 0.56. The stock’s 50 day moving average price is $45.83 and its two-hundred day moving average price is $42.77. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Qiagen had a return on equity of 14.69% and a net margin of 18.19%. The company had revenue of $547.87 million during the quarter, compared to analyst estimates of $538.61 million. During the same period in the previous year, the company earned $0.61 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, equities analysts forecast that Qiagen N.V. will post 2.44 earnings per share for the current year.

QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials.

The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.

Founded in 1984, QIAGEN serves customers in healthcare, academic and government research, pharmaceutical and biotechnology companies, and testing laboratories around the world.